ArticleEuropean journal of neurology2025
Video-Oculography as a Key Diagnostic Tool for SCA27B: A Real-Life Experience.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical and Genetic Characteristics of SCA27B: A Global Systematic Review and Meta-Analysis.Cerebellum (London, England) · 2026Pooled it
- Visual evoked potential abnormalities in spinocerebellar ataxia type 27B: a case report.Documenta ophthalmologica. Advances in ophthalmology · 2026Article
- Oculomotor abnormalities in patients with cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS) reflect midline cerebellar impairment.Journal of neurology · 2026Article
- Hereditary Ataxias: From Pathogenesis and Clinical Features to Neuroimaging, Fluid, and Digital Biomarkers-A Scoping Review.International journal of molecular sciences · 2026Review
- Downbeat Nystagmus and Saccadic Oscillations in Spinocerebellar Ataxia Type 27B: A 14-Month Follow-Up Case Report.Case reports in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpinocerebellar ataxia type 27B (SCA27B), caused by a GAA repeat expansion in FGF14, is a recently described genetic etiology of idiopathic late-onset cerebellar ataxia (ILOCA). Downbeat nystagmus (DBN) is increasingly recognized as a clinical hallmark of this condition. We aimed to assess the diagnostic value of video-oculography (VOG) in detecting SCA27B and its role in monitoring response to 4-aminopyridine (4-AP) in a real-world clinical setting.
methodsWe retrospectively analyzed patients with ILOCA referred to Fondation Rothschild Hospital (Paris, France) from February 2023 to January 2024. All underwent clinical, MRI, and VOG assessments, with genetic testing for FGF14-GAA expansions. Clinical and oculomotor features of carriers (≥ 200 repeats) and non-carriers were compared. A subset of symptomatic carriers received 4-AP and were evaluated at baseline, 2 months, and 8 months using the Scale for the Assessment and Rating of Ataxia (SARA) and VOG.
resultsTwelve of 34 tested patients (35%) were FGF14-GAA expansion carriers. DBN was significantly more frequent in carriers than in non-carriers (92% vs. 33%, p = 0.003), often associated with gaze-evoked nystagmus (75% vs. 19%, p = 0.005). MRI did not distinguish carriers from non-carriers. Of the nine patients treated, all reported enhanced balance, which is corroborated by the improvement in the SARA score from a median of 5.5-3 at 2 months (p = 0.015), with sustained benefit at 8 months.
conclusionsVOG is a key diagnostic tool for detecting DBN, which is strongly associated with SCA27B, facilitating targeted genetic testing. 4-AP is an effective symptomatic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.